MedTrace Logo

Non-inferiority Bioavailabilty Study of 3 Silicon-rich Supplements

NCT03108508 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-07-20

No results posted yet for this study

Summary

The objective of the present study is to evaluate the non-inferiority of the absorption parameters of three silicon supplements in human volunteers.

Conditions

  • Absorption; Disorder

Interventions

DIETARY_SUPPLEMENT

Prod1

60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.

DIETARY_SUPPLEMENT

Prod2

1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon

DIETARY_SUPPLEMENT

Prod3

120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon

Sponsors & Collaborators

  • SILICIUM ESPAÑA LABORATORIOS SLU

    collaborator UNKNOWN

  • Hospital Universitari Sant Joan de Reus

    collaborator OTHER

  • University Rovira i Virgili

    collaborator OTHER

  • Technological Centre of Nutrition and Health, Spain

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2017-06-30
Completion
2017-07-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108508 on ClinicalTrials.gov